Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan (ASH 2025) - Nov 4, 2025 - Abstract #abs25-7357; 1865; Pres time: Dec 6, 2025; 05:30 PM - 07:30 PM; Location: OCCC - West Halls B3-B4; P | "The median TTNT of each SA after 2nd- or later-linetherapies (mo, 95% CI) was 10.7 (3.9–17.3) for brentuximab vedotin (BV; n = 53, 21%), 5.0 (2.7–7.1) fortucidinostat (n = 36, 14%), 3.9 (2.6–4.8) for romidepsin (n = 80, 31%), 2.1 (0.4–5.2) for darinaparsin (n = 7,3%), 1.8 (1.3–2.5) for pralatrexate (n = 58, 23%), 1.5 (0.6–NE) for forodesine (n = 8, 3%), 1.1 (0.4–2.4) formogamulizumab (n = 22, 9%), 0.7 (0.4–3.5) for denileukin diftitox (n = 5, 2%), and NR (NE–NE) for alectinib(n = 1, 0.4%). In patients with TFHL, romidepsin (44%) and tucidinostat (18%) yielded median TTNTs (mo,95% CI) of 4.0 (2.6–8.7) and 5.5 (1.9–7.8), respectively... To the best of our knowledge, this study reports the most recent treatment patterns andprognoses for patients with R/R MTNKL. No standard of care has been established, as diverse treatmentpatterns have been observed. SAs resulted in similar survival outcomes to CCs in 2nd-line therapy,despite distinctive clinical Background of the...
Clinical • Observational data • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Dermatology • Extranodal Natural Killer/T-cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Natural Killer/T-cell Lymphoma • Non-Hodgkin's Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK
|
|
Hideki Uryu1; Tsuyoshi Muta2; Mitsumasa Watanabe3; Kosei Matsue4; Tatsuo Ichinohe5; Atsushi Takahata6; Masashi Sawa7; Nobuyuki Takayama8; Takafumi Yokota9; Hiromichi Takahashi10; Nobuhiko Yamauchi11; Taku Tsukamoto12; Kunihiro Tsukasaki13; Motoaki Shiratsuchi14; Kentaro Ido15; Yasushi Takamatsu16; Kisato Nosaka17; Tadakazu Kondo18; Tomoko Narita19; Junichiro Yuda20; Masaki Hayashi21; Ryosuke Naka22; Hiroaki Fujimori22; Yuichi Baba22; Mitsufumi Nishio22; Kenji Ishitsuka23; Koji Izutsu24
|